medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2012, Number 4

<< Back Next >>

Biotecnol Apl 2012; 29 (4)

Physiological and nutritional studies of Escherichia coli and a new combination of separation methods to obtain highly pure and homogeneous plasmid DNA for gene therapy

Ruiz O, Limonta M, Valdés J, Márquez G, Díaz M, Frómeta W, Pupo M, Torres D, Martínez E, Dueñas-Carrera S

Language: English
References: 10
Page: 271-274
PDF size: 133.85 Kb.


ABSTRACT

A scalable high-cell-density Escherichia coli culture method was established to obtain pharmaceutical grade plasmid DNA (pDNA), together with an optimized purification process. The effects of several components of the medium, such as carbon and nitrogen sources that ensure bacterial nutritional needs, were studied. The operation parameters, such as temperature, shaking and aeration, were set and the optimum values of cell growth and specific pDNA productivity in culture were determined. The subsequent purification process for pharmaceutical grade pDNA was implemented, by combining RNA precipitation with ammonium sulfate and two successive chromatographic steps consisting of size exclusion chromatography and reverse phase-high performance liquid chromatography. This work comprised the first report on the use of reverse phase to purify DNA for application in humans.


REFERENCES

  1. Ruiz O, Limonta M, Valdes J, Pupo M, Martínez E. Scalable technology to produce pharmaceutical grade plasmid DNA for gene therapy. In: Kang C, editor. Gene Therapy - developments and future perspectives; Rijeka: Intech Europe; 2011. p. 53-70.

  2. Diogo MM, Queiroz JA, Monteiro GA, Martins SA, Ferreira GN, Prazeres DM. Purification of a cystic fibrosis plasmid vector for gene therapy using hydrophobic interaction chromatography. Biotechnol Bioeng. 2000;68(5):576-83.

  3. Limonta M, Márquez G, Rey I, Pupo M, Ruiz O, Amador-Cañizares Y, et al. Plasmid DNA recovery using size-exclusion and perfusion chromatography. Biopharm Int. 2008;21(9):38-47.

  4. Yee L, Blanch HW. Recombinant trypsin production in high cell density fed-batch cultures in Escherichia coli. Biotechnol Bioeng. 1993;41(8):781-90.

  5. Piatkin K, Krivoshein Y. Microbiología. Moscú: Mir; 1986.

  6. Ruiz O, Pérez M, Pupo M, Limonta M, Torres D, Martínez S, et al. High-cell-density culture to produce plasmid DNA for gene therapy in E. coli. Biopharm Int. 2009;22(7):40-5.

  7. Ferreira GN, Cabral JM, Prazeres DM. Development of process flow sheets for the purification of supercoiled plasmids for gene therapy applications. Biotechnol Prog. 1999;15(4):725-31.

  8. Horn NA, Meek JA, Budahazi G, Marquet M. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther. 1995;6(5):565-73.

  9. Food and Drug Administration (FDA). Guidance for Industry: Considerations for Plasmid DNA vaccines for Infectious Disease Indications. Rockville, MD: FDA; 2005 Feb.

  10. Limonta M, Márquez G, Pupo M, Ruiz O. The purification of plasmid DNA for clinical trials using membrane chromatography. Biopharm Int. 2010;23(2):46-54.




2020     |     www.medigraphic.com